HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA

This article was originally published in The Rose Sheet

Executive Summary

CHPA and CRN look forward to working with FDA to develop a path for the identification of pre-DSHEA ingredients, but say the FDA’s revised draft guidance for new dietary ingredient notifications still hampers innovation.

You may also be interested in...



US Supplement Market Growth: Is The Industry In Its Own Way?

Longtime supplement industry attorney Scott Bass says supplement manufacturers should work with FDA as an ally, including registering products with the agency pre-market, while FDA's second-in-command for supplement industry oversight, Robert Durkin, says the agency is not interested in preventing more safe products from reaching the market.

FDA Plans For Soy Health Claims, Pyridoxamine's Use Questioned By CRN, NPA

FDA’s proposed rule to revoke soy protein heart health ignores research supporting the claims and cites evidence that isn't compelling, CRN an NPA say in comments to the agency. CRN also submits comments supporting an ingredient firm's petition asking FDA to remove any uncertainty about the of use of pyridoxamine as a dietary ingredient.

GAO Memory Supplement Review Recalls FDA's Regulatory Challenges

GAO recommends better cooperation between FDA and FTC and more public outreach are key to preventing consumers from believing noncompliant cognitive benefit claims for supplements.

Related Content

Topics

UsernamePublicRestriction

Register

RS109294

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel